Identification of amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment

Diabetes Care

Volumn 28, Issue 3, 2005, Pages 645-652

  Jaleel, Abdul ^a   Halvatsiotis, Panagiotis ^a   Willlamson, Brian ^b   Juhasz, Peter ^b   Martin, Stephen ^b   Nair, K Sreekumaran ^a  

^a MAYO CLINIC   (United States)

^b Applied Biosystems Framingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYFRUCTOSYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALPHA FIBRINOGEN PRECURSOR; ANTIBODY; BETA FIBRINOGEN PRECURSOR; FIBRIN; FIBRINOGEN; HEMOPEXIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INSULIN; LYSINE DERIVATIVE; PLASMA PROTEIN; SERINE PROTEINASE INHIBITOR; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADULT; AMADORI REARRANGEMENT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; GLYCATION; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN ANALYSIS; PROTEIN MODIFICATION; SHORT COURSE THERAPY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOOD GLUCOSE; BLOOD PROTEINS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FRUCTOSAMINE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; INSULIN; MIDDLE AGED; OBESITY; SERUM ALBUMIN; SERUM GLOBULINS; THINNESS;

EID: 14644435071     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.3.645     Document Type: Article

References (43)

1. Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 81:583-587, 1984
2. Monnier VM, Stevens VJ, Cerami A: Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog Food Nutr Sci 5:315-327, 1981
3. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314:403-408, 1986
4. Cohen MP, Urdanivia E, Surma M, Wu VY: Increased glycosylation of glomerular basement membrane collagen in diabetes. Biochem Biophys Res Commun 95:765-769, 1980
5. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 91:9441-9445, 1994
6. Brownlee M, Vlassara H, Cerami A: Non-enzymat glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101:527-537, 1984
7. Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 4: 437-451, 1988
8. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
9. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
10. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588, 2002
11. Stitt AW, Jenkins AJ, Cooper ME: Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 11:1205-1223, 2002
12. Stitt A, Gardiner TA, Anderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832, 2002
13. Sato E, Mori F, Igarashi S, Abiko T, Takeda M, Ishiko S, Yoshida A: Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 24:479-482, 2001
14. Yamagishi S, Takeuchi M, Makita Z: Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib Nephrol 134:30-35, 2001
15. Mene P, Festuccia F, Polci R, Pugliese F, Cinotti GA: Diabetic nephropathy and advanced glycation end products. Contrib Nephrol 131:22-32, 2001
16. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38 (Suppl. 1):S100-S106, 2001
17. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 35:365-380, 2000
18. King RH: The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 54:400-408, 2001
19. Thornalley PJ: Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 50:37-57, 2002
20. Lapolla A, Tonani R, Fedele D, Garbeglio M, Senesi A, Seraglia R, Favretto D, Traldi P: Non-enzymatic glycation of IgG: an in vivo study. Horm Metab Res 34:260-264, 2002
21. Wautier JL, Wautier MP: Blood cells and vascular cell interactions in diabetes. Clin Hemorheol Microcirc 25:49-53, 2001
22. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K: Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 14:475-486, 2001
23. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HG, Schlingemann RO, Tarnow L, Parving HH, Stehouwer CD, van Hinsbergh VW: Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48:2446-2453, 1999
24. Schalkwijk CG, Chaturvedi N, Twaafhoven H, van Hinsbergh VW, Stehouwer CD: Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest 32:500-506, 2002
25. Londono I, Bendayan M: Temporary effects of circulating Amadori products on glomerular filtration properties in the normal mouse. Am J Physiol Renal Physiol 280:F103-F111, 2001
26. Cohen MP, Masson N, Hud E, Ziyadeh F, Han DC, Clements RS: Inhibiting albumin glycation ameliorates diabetic nephropathy in the db/db mouse. Exp Nephrol 8:135-143, 2000
27. Hattori Y, Suzuki M, Hattori S, Kasai K: Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 39:22-28, 2002
28. Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN: Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 59:673-681, 2001
29. Allgrove J, Cockrill BL: Fructosamine or glycated haemoglobin as a measure of diabetic control? Arch Dis Child 63:418-422, 1988
30. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
31. Halvatsiotis P, Short KR, Bigelow M, Nair KS: Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes. Diabetes 51:2395-2404, 2002
32. Bergman RN, Cobelli C: Minimal modeling, partition analysis, and the estimation of insulin sensitivity. Fed Proc 39:110-115, 1980
33. Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 236:E667-E677, 1979
34. Vlassara H, Brownlee M, Cerami A: Non-enzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem 32:B37-B41, 1986
35. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A: Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 295:417-420, 1976
36. Dolhofer R, Siess EA, Wieland OH: Non-enzymatic glycation of immunoglobulins leads to an impairment of immunoreactivity. Biol Chem Hoppe Seyler 366:361-366, 1985
37. Hennessey PS, Back CT, Andrassy RJ: Non-enzymatic glycosylation of immunoglobulin G impairs complement fixation. J Parent Ent Nutr 15:60-64, 1991
38. Brownlee M, Vlassara H, Cerami A: Non-enzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32:680-684, 1983
39. Arnesen H: Introduction: the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 20:51-4, 1992
40. Fujimoto S, Kawakami N, Ohara A: Non-enzymatic glycation of transferrin: decrease of iron-binding capacity and increase of oxygen radical production. Biol Pharm Bull 18:396-400, 1995
41. 4L Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus (Letter). N Engl J Med 329:977-986, 1993
42. Glaser B, Leibovich G, Nesher R, Hartling S, Binder C, Cerasi E: Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acta Endocrinologica 118:365-373, 1988
43. Samanta A, Burden AC, Jones GR, Clarkson L: The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Diabetes Res 3:269-271, 1986